Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H

HHKEX:8189
0.17
HKD
-0.01
(-5.71%)
143.55MMarket Cap
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H
HKEX:8189
(Hong Kong Exchange)

Recent

price

0.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.3
0.36
0.48
0.41
0.33
0.33
0.24
0.22
0.19
0.19
0.19
0.25
0.21
0.21
0.2
0.25
- -
Revenue per Share
- -
0.01
0.02
0.02
0.01
0.02
- -
-0.01
-0.1
-0.04
-0.03
-0.02
-0.01
-0.01
-0.01
-0.04
- -
Basic EPS, GAAP
-0.02
-0.03
0.01
-0.01
- -
-0.03
-0.01
-0.02
-0.02
- -
0.01
-0.02
-0.01
-0.01
-0.02
-0.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.1
0.11
0.13
0.14
0.14
0.2
0.2
0.25
0.14
0.1
0.08
0.05
0.04
0.03
0.01
0.01
0.02
Book Value per Share
0.1
0.11
0.12
0.14
0.14
0.2
0.2
0.08
0.12
0.09
0.07
0.05
0.02
0.02
- -
- -
0.02
Tangible Book Value per Share
1,420
1,420
1,420
1,420
1,420
1,542
1,595
1,674
1,855
1,895
1,895
1,895
1,895
1,895
1,895
2,080
1,894
Basic Weighted Avg Shares
429
511
678
583
470
502
389
376
352
359
369
476
404
398
385
523
- -
Sales/Revenue/Turnover
2.77
4.15
5.65
5.9
7.13
7.16
4.23
-1.54
-16.76
-5.45
-1.32
-1.29
-4.76
-2.47
-3.93
1.21
- -
Operating Margin (%)
9
10
9
9
9
11
9
21
24
15
7
10
15
12
9
9
- -
Depreciation Expense
6
14
24
21
18
26
6
-14
-178
-85
-48
-42
-27
-20
-28
-91
- -
Net Income, GAAP
- -
14.15
21.69
10.53
26.97
14.09
47.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1.43
2.82
3.54
3.67
3.78
5.1
1.53
-3.66
-50.49
-23.59
-13
-8.87
-6.8
-5.07
-7.21
-17.37
- -
Profit Margin (%)
53
75
101
136
136
245
261
175
137
98
66
17
-25
-27
-45
-62
-24
Working Capital
5
- -
- -
- -
- -
- -
- -
- -
- -
- -
43
45
35
20
24
9
25
LT Debt
167
178
203
225
244
344
349
575
292
206
155
110
81
65
28
3
59
Total Equity
- -
8.34
10.62
9.42
7.51
8.75
2.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
6.92
10.55
8.94
5.98
8.93
2.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
4.45
9.71
14.29
11.21
8.91
9.87
1.85
-3.67
-51.06
-36.47
-28.74
-34.66
-32.13
-33.58
-77.12
-528.44
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
57
85
LT Borrowings
- -
10
15
LT Finance Leases
- -
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,895
1,895
1,895
Market Capitalization
167
153
134

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
190
200
Cash, Cash Equivalents & STI
- -
6
18
Accounts Receivable, Net
- -
9
10
Inventories
- -
90
80
Total Current Liabilities
- -
217
224
Payables & Accruals
- -
- -
- -
ST Debt
- -
57
85
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-25.95%
-44.42%
-90.39%
Free Cash Flow
-54.85%
-31.11%
117.98%
Net Income, GAAP
88.04%
38.2%
226.67%
Sales/Revenue/Turnover
1.75%
8.97%
35.67%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
398
2024
- -
- -
385
2025
- -
- -
523

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.01
2024
- -
- -
-0.01
2025
- -
- -
-0.04

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) engages in the research, development, manufacture, and sale of biological compound fertilizer products and provides elderly care and health care services in the People's Republic of China. The company offers active fertilizers and mixtures containing nitrogen, phosphorus, and potassium in various formulas to promote balanced growth of grains, fruits, and vegetables; warehousing, processing, and licensing of fertilizer products; integrated elderly care services including equipment leasing, consulting, advisory, management, and assessment; electroencephalography (EEG) diagnosis detection and related technology services; regional soil resources conditioning and remediation; soil environmental quality standards research; biomedical science and technology projects; and trading of wine alongside system platform development. It operates primarily through two segments—Fertiliser Products and Elderly Care & Health Care Services—targeting agricultural producers and elderly populations across China, with additional involvement in information technology services. Founded in 2000 and headquartered in Tianjin, China, the company recently signed a strategic cooperation agreement with Shanghai Suihong Huachuang Technology in August 2025 for AI medical health initiatives; entered a strategic partnership with China Telecom Ningxia for medical and healthcare big data; and completed the acquisition of Shanghai Weidi Network Technology Company in 2022.